Fortress Biotech (FBIO) Amortization of Deferred Charges (2013 - 2017)

Fortress Biotech's Amortization of Deferred Charges history runs 11 years deep, the most recent figure standing at $476000.0 for Q4 2025.

• In Q4 2025, Amortization of Deferred Charges fell 0.83% year-over-year to $476000.0; the TTM figure through Dec 2025 stood at $1.9 million (down 31.73% YoY), while the FY2025 annual figure was $1.9 million, down 31.73% from the prior year.
• Amortization of Deferred Charges for Q4 2025 stood at $476000.0, down from $496000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $1.4 million in Q2 2024, with the low at $415000.0 in Q1 2021.
• The 5-year median for Amortization of Deferred Charges is $485500.0 (2025), against an average of $526150.0.
• The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges surged 158.52% in 2024, then sank 64.4% in 2025.
• Fortress Biotech's Amortization of Deferred Charges stood at $430000.0 in 2021, then climbed by 26.05% to $542000.0 in 2022, then retreated by 4.61% to $517000.0 in 2023, then decreased by 7.16% to $480000.0 in 2024, then retreated by 0.83% to $476000.0 in 2025.
• Business Quant data shows FBIO's Amortization of Deferred Charges at $476000.0 in Q4 2025, $496000.0 in Q3 2025, and $486000.0 in Q2 2025.